Home	Fast Track My Amedeo FAQ About	Flying Publisher
Fast Track	Hepatology 2012 (546 pages, free PDF) Hepatitis C 2012 (150 pages, free PDF)	Free Medical Books

Hepatitis C

Free Subscription Articles published in J Infect Dis Retrieve available abstracts of 74 articles: HTML format Text format

Single Articles

April 2012
1. THIBAULT V , Bara JL, Duplessy-Garson C
   Reply to: Hepatitis C Virus Transmission in People Who Inject Drugs: Swabs May Not Be The Main Culprit.
   J Infect Dis. 2012.
   PubMed     Text format     Related articles   
   
   
   
   
2. MAHER L , Wand H
   Hepatitis C Virus Transmission in People Who Inject Drugs: Swabs May Not Be The Main Culprit.
   J Infect Dis. 2012.
   PubMed     Text format     Related articles   
   
   
   
   March 2012
3. VICKERMAN P , Grebely J, Dore GJ, Sacks-Davis R, et al
   The More You Look, the More You Find: Effects of Hepatitis C Virus Testing Interval on Reinfection Incidence and Clearance and Implications for Future Vaccine Study Design.
   J Infect Dis. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
4. STEGMANN KA , Bjorkstrom NK, Ciesek S, Lunemann S, et al
   Interferon alpha-Stimulated Natural Killer Cells From Patients With Acute Hepatitis C Virus (HCV) Infection Recognize HCV-Infected and Uninfected Hepatoma Cells via DNAX accessory molecule-1.
   J Infect Dis. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
5. KATZ LM
   How can the blood transfusion medicine community contribute to public health in tough economic times?
   J Infect Dis. 2012;205:867-9.
   PubMed     Text format     Related articles   
   
   
   
   February 2012
6. TOKUMOTO Y , Hiasa Y, Uesugi K, Watanabe T, et al
   Ribavirin Regulates Hepatitis C Virus Replication Through Enhancing Interferon-Stimulated Genes and Interleukin 8.
   J Infect Dis. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
7. GRAFMUELLER S , Billerbeck E, Blum HE, Neumann-Haefelin C, et al
   Differential Antigen Specificity of Hepatitis C Virus-Specific Interleukin 17- and Interferon gamma-Producing CD8+ T Cells During Chronic Infection.
   J Infect Dis. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
8. CONRY SJ , Meng Q, Hardy G, Yonkers NL, et al
   Genetically Associated CD16+56- Natural Killer Cell Interferon (IFN)-alphaR Expression Regulates Signaling and Is Implicated in IFN-alpha-Induced Hepatitis C Virus Decline.
   J Infect Dis. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
9. ZHU H , Wong-Staal F, Lee H, Syder A, et al
   Evaluation of ITX 5061, a Scavenger Receptor B1 Antagonist: Resistance Selection and Activity in Combination With Other Hepatitis C Virus Antivirals.
   J Infect Dis. 2012;205:656-62.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   January 2012
10. DELWART E , Slikas E, Stramer SL, Kamel H, et al
    Genetic Diversity of Recently Acquired and Prevalent HIV, Hepatitis B Virus, and Hepatitis C Virus Infections in US Blood Donors.
    J Infect Dis. 2012.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
11. RAGHURAMAN S , Park H, Osburn WO, Winkelstein E, et al
    Spontaneous Clearance of Chronic Hepatitis C Virus Infection Is Associated With Appearance of Neutralizing Antibodies and Reversal of T-Cell Exhaustion.
    J Infect Dis. 2012.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    December 2011
12. NAGGIE S , Rallon NI, Benito JM, Morello J, et al
    Variants in the ITPA Gene Protect Against Ribavirin-Induced Hemolytic Anemia in HIV/HCV-Coinfected Patients With All HCV Genotypes.
    J Infect Dis. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    November 2011
13. OCHI H , Hayes CN, Abe H, Hayashida Y, et al
    Toward the Establishment of a Prediction System for the Personalized Treatment of Chronic Hepatitis C.
    J Infect Dis. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    October 2011
14. SHEBL FM , Pfeiffer RM, Buckett D, Muchmore B, et al
    IL28B rs12979860 Genotype and Spontaneous Clearance of Hepatitis C Virus in a Multi-Ethnic Cohort of Injection Drug Users: Evidence for a Supra-Additive Association.
    J Infect Dis. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
15. HAGAN H
    Agent, Host, and Environment: Hepatitis C Virus in People Who Inject Drugs.
    J Infect Dis. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
16. THIBAULT V , Bara JL, Nefau T, Duplessy-Garson C, et al
    Hepatitis C Transmission in Injection Drug Users: Could Swabs Be the Main Culprit?
    J Infect Dis. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
17. DOERRBECKER J , Friesland M, Ciesek S, Erichsen TJ, et al
    Inactivation and Survival of Hepatitis C Virus on Inanimate Surfaces.
    J Infect Dis. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
18. MEUNIER JC , Bukh J, Diaz G, Tovo PA, et al
    Neutralizing Antibodies to Hepatitis C Virus in Perinatally Infected Children Followed Up Prospectively.
    J Infect Dis. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
19. CHATTERGOON MA , Levine JS, Latanich R, Osburn WO, et al
    High Plasma Interleukin-18 Levels Mark the Acute Phase of Hepatitis C Virus Infection.
    J Infect Dis. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
20. MEUNIER JC , Gottwein JM, Houghton M, Russell RS, et al
    Vaccine-induced cross-genotype reactive neutralizing antibodies against hepatitis C virus.
    J Infect Dis. 2011;204:1186-90.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
21. KATSOUNAS A , Trippler M, Kottilil S, Lempicki RA, et al
    Altered Expression of SHIP, a Toll-like Receptor Pathway Inhibitor, Is Associated With the Severity of Liver Fibrosis in Chronic Hepatitis C Virus Infection.
    J Infect Dis. 2011;204:1181-5.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
22. SATOH M , Saito M, Takano T, Kasama Y, et al
    Monoclonal Antibody 2-152a Suppresses Hepatitis C Virus Infection Through Betaine/GABA Transporter-1.
    J Infect Dis. 2011;204:1172-80.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    September 2011
23. KURBANOV F , Abdel-Hamid M, Latanich R, Astemborski J, et al
    Genetic Polymorphism in IL28B Is Associated With Spontaneous Clearance of Hepatitis C Virus Genotype 4 Infection in an Egyptian Cohort.
    J Infect Dis. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
24. VERSTREPEN BE , Depla E, Rollier CS, Mares G, et al
    Clearance of genotype 1b hepatitis C virus in chimpanzees in the presence of vaccine-induced e1-neutralizing antibodies.
    J Infect Dis. 2011;204:837-44.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
25. ZEREMSKI M , Dimova R, Astemborski J, Thomas DL, et al
    CXCL9 and CXCL10 Chemokines as Predictors of Liver Fibrosis in a Cohort of Primarily African-American Injection Drug Users With Chronic Hepatitis C.
    J Infect Dis. 2011;204:832-6.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
26. SMITH BD , Drobeniuc J, Jewett A, Branson BM, et al
    Evaluation of three rapid screening assays for detection of antibodies to hepatitis C virus.
    J Infect Dis. 2011;204:825-31.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
27. TAMURA R , Kanda T, Imazeki F, Wu S, et al
    Hepatitis C Virus Nonstructural 5A Protein Inhibits Lipopolysaccharide-Mediated Apoptosis of Hepatocytes by Decreasing Expression of Toll-Like Receptor 4.
    J Infect Dis. 2011;204:793-801.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    August 2011
28. SCOTT J , Holte S, Urban T, Burgess C, et al
    IL28B Genotype Effects During Early Treatment with Peginterferon and Ribavirin in Difficult-to-Treat Hepatitis C Virus Infection.
    J Infect Dis. 2011;204:419-25.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
29. PENG LF , Schaefer EA, Maloof N, Skaff A, et al
    Ceestatin, a novel small molecule inhibitor of hepatitis C virus replication, inhibits 3-hydroxy-3-methylglutaryl-coenzyme a synthase.
    J Infect Dis. 2011;204:609-16.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
30. FORESTIER N , Larrey D, Marcellin P, Guyader D, et al
    Antiviral Activity of Danoprevir (ITMN-191/RG7227) in Combination With Pegylated Interferon {alpha}-2a and Ribavirin in Patients With Hepatitis C.
    J Infect Dis. 2011;204:601-8.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    July 2011
31. STAMATAKI Z , Coates S, Abrignani S, Houghton M, et al
    Immunization of Human Volunteers With Hepatitis C Virus Envelope Glycoproteins Elicits Antibodies That Cross-Neutralize Heterologous Virus Strains.
    J Infect Dis. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
32. CHAYAMA K , Hayes CN, Abe H, Miki D, et al
    IL28B But Not ITPA Polymorphism Is Predictive of Response to Pegylated Interferon, Ribavirin, and Telaprevir Triple Therapy in Patients With Genotype 1 Hepatitis C.
    J Infect Dis. 2011;204:84-93.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
33. HAGAN H , Pouget ER, Des Jarlais DC
    A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs.
    J Infect Dis. 2011;204:74-83.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    June 2011
34. KUNIHOLM MH , Gao X, Xue X, Kovacs A, et al
    The Relation of HLA Genotype to Hepatitis C Viral Load and Markers of Liver Fibrosis in HIV-Infected and HIV-Uninfected Women.
    J Infect Dis. 2011;203:1807-14.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
35. REIBERGER T , Payer BA, Kosi L, Heil PM, et al
    Concomitant Highly Active Antiretroviral Therapy Leads to Smaller Decline and Faster Recovery of CD4+ Cell Counts During and After Pegylated Interferon Plus Ribavirin Therapy in HIV-Hepatitis C Virus Coinfected Patients.
    J Infect Dis. 2011;203:1802-1806.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
36. BANDYOPADHYAY S , Friedman RC, Marquez RT, Keck K, et al
    Hepatitis C Virus Infection and Hepatic Stellate Cell Activation Downregulate miR-29: miR-29 Overexpression Reduces Hepatitis C Viral Abundance in Culture.
    J Infect Dis. 2011;203:1753-62.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
37. LINDH M , Lagging M, Farkkila M, Langeland N, et al
    Interleukin 28B Gene Variation at rs12979860 Determines Early Viral Kinetics During Treatment in Patients Carrying Genotypes 2 or 3 of Hepatitis C Virus.
    J Infect Dis. 2011;203:1748-52.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
38. BARREIRO P , Pineda JA, Rallon N, Naggie S, et al
    Influence of Interleukin-28B Single-Nucleotide Polymorphisms on Progression to Liver Cirrhosis in Human Immunodeficiency Virus-Hepatitis C Virus-Coinfected Patients Receiving Antiretroviral Therapy.
    J Infect Dis. 2011;203:1629-36.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    May 2011
39. KANG J , Blalock GR, Dimitrov JD
    Thermodynamic Analysis of Hepatitis C Virus Vitality in Syringes.
    J Infect Dis. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
40. COLSON P , Gerolami R
    Two Years' Persistence of Naturally Present Substitution R155K Within Hepatitis C Virus NS3 Protease in the Absence of Protease Inhibitor-based Therapy.
    J Infect Dis. 2011;203:1341-2.
    PubMed     Text format     Related articles   
    
    
    
    
41. SIMMONS R , Sharp C, Sims S, Kloverpris H, et al
    High Frequency, Sustained T Cell Responses to PARV4 Suggest Viral Persistence In Vivo.
    J Infect Dis. 2011;203:1378-87.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    March 2011
42. YONEDA S , Umemura T, Katsuyama Y, Kamijo A, et al
    Association of Serum Cytokine Levels with Treatment Response to Pegylated Interferon and Ribavirin Therapy in Genotype 1 Chronic Hepatitis C Patients.
    J Infect Dis. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
43. GREBELY J , Dore GJ
    Prevention of hepatitis C virus in injecting drug users: a narrow window of opportunity.
    J Infect Dis. 2011;203:571-4.
    PubMed     Text format     Related articles   
    
    
    
    
44. THURAIRAJAH PH , Hegazy D, Demaine A, Kaminski ER, et al
    Loss of Virus-specific T-Cell Responses in HCV Exposed Uninfected Injection Drug Users With Drug Rehabilitation.
    J Infect Dis. 2011;203:847-53.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
45. MEHTA SH , Astemborski J, Kirk GD, Strathdee SA, et al
    Changes in Blood-borne Infection Risk Among Injection Drug Users.
    J Infect Dis. 2011;203:587-94.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    January 2011
46. NATTERMANN J , Vogel M, Nischalke HD, Danta M, et al
    Genetic Variation in IL28B and Treatment-Induced Clearance of Hepatitis C Virus in HIV-Positive Patients With Acute and Chronic Hepatitis C.
    J Infect Dis. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
47. HASHEM M , El-Karaksy H, Shata MT, Sobhy M, et al
    Strong Hepatitis C Virus (HCV)-specific Cell-mediated Immune Responses in the Absence of Viremia or Antibodies Among Uninfected Siblings of HCV Chronically Infected Children.
    J Infect Dis. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
48. YONKERS NL , Sieg S, Rodriguez B, Anthony DD, et al
    Reduced Naive CD4 T Cell Numbers and Impaired Induction of CD27 in Response to T Cell Receptor Stimulation Reflect a State of Immune Activation in Chronic Hepatitis C Virus Infection.
    J Infect Dis. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
49. BABIK JM , Cohan D, Monto A, Hartigan-O'Connor DJ, et al
    The human fetal immune response to hepatitis C virus exposure in utero.
    J Infect Dis. 2011;203:196-206.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    November 2010
50. LE POGAM S , Seshaadri A, Ewing A, Kang H, et al
    RG7128 Alone or in Combination with Pegylated Interferon-alpha2a and Ribavirin Prevents Hepatitis C Virus (HCV) Replication and Selection of Resistant Variants in HCV-Infected Patients.
    J Infect Dis. 2010;202:1510-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
51. IRVING WL , Brown RJ
    Acute Hepatitis C Virus Infection: A Dynamic-and Challenging-Concept.
    J Infect Dis. 2010.
    PubMed     Text format     Related articles   
    
    
    
    October 2010
52. SMITH JA , Aberle JH, Fleming VM, Ferenci P, et al
    Dynamic Coinfection with Multiple Viral Subtypes in Acute Hepatitis C.
    J Infect Dis. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
53. MARTIN MP , Qi Y, Goedert JJ, Hussain SK, et al
    IL28B Polymorphism Does Not Determine Outcomes of Hepatitis B Virus or HIV Infection.
    J Infect Dis. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
54. MANSOUR H , Laird ME, Saleh R, Casrouge A, et al
    Circulating Plasmacytoid Dendritic Cells in Acutely Infected Patients with Hepatitis C Virus Genotype 4 Are Normal in Number and Phenotype.
    J Infect Dis. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
55. BARNES E , Flanagan P, Brown A, Robinson N, et al
    Failure to Detect Xenotropic Murine Leukemia Virus–Related Virus in Blood of Individuals at High Risk of Blood‐Borne Viral Infections.
    J Infect Dis. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    September 2010
56. MORELLO J , Cuenca L, Soriano V, Medrano J, et al
    Influence of a Single Nucleotide Polymorphism at the Main Ribavirin Transporter Gene on the Rapid Virological Response to Pegylated Interferon-Ribavirin Therapy in Patients with Chronic Hepatitis C Virus Infection.
    J Infect Dis. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    August 2010
57. RICH JD , Taylor LE
    The Beginning of a New Era in Understanding Hepatitis C Virus Prevention.
    J Infect Dis. 2010.
    PubMed     Text format     Related articles   
    
    
    
    
58. PAINTSIL E , He H, Peters C, Lindenbach BD, et al
    Survival of Hepatitis C Virus in Syringes: Implication for Transmission among Injection Drug Users.
    J Infect Dis. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
59. GYARMATHY VA
    Receptive syringe sharing and infection risk: to clean or not to clean.
    J Infect Dis. 2010;202:499.
    PubMed     Text format     Related articles   
    
    
    
    
60. KUCIRKA LM , Farzadegan H, Feld JJ, Mehta SH, et al
    Prevalence, Correlates, and Viral Dynamics of Hepatitis Delta among Injection Drug Users.
    J Infect Dis. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
61. BURBELO PD , Kovacs JA, Ching KH, Issa AT, et al
    Proteome-wide Anti-Hepatitis C Virus (HCV) and Anti-HIV Antibody Profiling for Predicting and Monitoring the Response to HCV Therapy in HIV-Coinfected Patients.
    J Infect Dis. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
62. RAY R , Meyer K, Banerjee A, Basu A, et al
    Characterization of Antibodies Induced by Vaccination with Hepatitis C Virus Envelope Glycoproteins.
    J Infect Dis. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
63. CHARY A , Winters MA, Kottilil S, Murphy AA, et al
    Impact of Interferon-Ribavirin Treatment on Hepatitis C Virus (HCV) Protease Quasispecies Diversity in HIV- and HCV-Coinfected Patients.
    J Infect Dis. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    July 2010
64. CHUNG H , Watanabe T, Kudo M, Chiba T, et al
    Hepatitis C Virus Core Protein Induces Homotolerance and Cross-Tolerance to Toll-Like Receptor Ligands by Activation of Toll-Like Receptor 2.
    J Infect Dis. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
65. MURPHY EL , Fang J, Tu Y, Cable R, et al
    Hepatitis C Virus Prevalence and Clearance among US Blood Donors, 2006-2007: Associations with Birth Cohort, Multiple Pregnancies, and Body Mass Index.
    J Infect Dis. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    May 2010
66. SHIRASAKI T , Honda M, Mizuno H, Shimakami T, et al
    La Protein Required for Internal Ribosome Entry Site-Directed Translation Is a Potential Therapeutic Target for Hepatitis C Virus Replication.
    J Infect Dis. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
67. REIBERGER T , Kosi L, Maresch J, Breitenecker F, et al
    Mitochondrial Toxicity Is Associated with Virological Response in Patients with HIV and Hepatitis C Virus Coinfection Treated with Ribavirin and Highly Active Antiretroviral Therapy.
    J Infect Dis. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
68. EINAV S , Sobol HD, Gehrig E, Glenn JS, et al
    The Hepatitis C Virus (HCV) NS4B RNA Binding Inhibitor Clemizole Is Highly Synergistic with HCV Protease Inhibitors.
    J Infect Dis. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
69. YU ML , Lee CM, Chuang WL, Lu SN, et al
    HBsAg Profiles in Patients Receiving Peginterferon Alfa-2a plus Ribavirin for the Treatment of Dual Chronic Infection with Hepatitis B and C Viruses.
    J Infect Dis. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
70. NYSTROM J , Chen A, Frelin L, Ahlen G, et al
    Improving on the Ability of Endogenous Hepatitis B Core Antigen to Prime Cytotoxic T Lymphocytes.
    J Infect Dis. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
71. CIESEK S , Friesland M, Steinmann J, Becker B, et al
    How Stable Is the Hepatitis C Virus (HCV)? Environmental Stability of HCV and Its Susceptibility to Chemical Biocides.
    J Infect Dis. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    April 2010
72. KURBANOV F , Tanaka Y, Matsuura K, Sugauchi F, et al
    Positive Selection of Core 70Q Variant Genotype 1b Hepatitis C Virus Strains Induced by Pegylated Interferon and Ribavirin.
    J Infect Dis. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    March 2010
73. BUKH J , Meuleman P, Tellier R, Engle RE, et al
    Challenge Pools of Hepatitis C Virus Genotypes 1-6 Prototype Strains: Replication Fitness and Pathogenicity in Chimpanzees and Human Liver-Chimeric Mouse Models.
    J Infect Dis. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
74. MOSBRUGER TL , Duggal P, Goedert JJ, Kirk GD, et al
    Large-Scale Candidate Gene Analysis of Spontaneous Clearance of Hepatitis C Virus.
    J Infect Dis. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    

Thank you for your interest in scientific medicine.

This service is provided by AMEDEO through an unrestricted educational grant from F. Hoffmann-La Roche.

Amedeo is a Flying Publisher website.    Design: